Abstract：【Objective】 To analyze the clinical efficacy and safety of pirarubicin, gemcitabine and cisplatin in the treatment of advanced bladder cancer. 【Methods】 A total of 575 patients with advanced bladder cancer were randomly divided into the control group (286 cases) and the research group (289 cases). Patients in the control group received gemcitabine and cisplatin treatment, while patients in the research group received pirarubicin in addition to gemcitabine and ciaplatin. The clinical efficacy, tumor markers, safety and survival of the two groups were compared. 【Results】 The total effective rate in the research group was 77.51% (224/289), which was significantly higher than that of the control group (51.75%, 148/286). The difference was statistically significant (P<0.05). Serum fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and secretory protein (DKK) levels decreased in both groups compared with before treatment, Levels in the research group were significantly lower than those in the control group(P<0.05). There was no significant difference in the incidence of nausea and vomiting, neutropenia, and rash between the two groups(P>0.05). The incidence of thrombocytopenia, alopecia, and fatigue in the research group was higher than that in the control group. The difference was statistically significant between the two groups (P<0.05). The 1-year and 2-year overall survival rates of the resaerch group were 83.74%(242/289)and 61.25%(177/289), respectively, which were higher than the control group's 61.19%(175/286)and 35.31%(101/286), respectively (P<0.05). 【Conclusion】 Clinical efficacy of pirarubicin, gemcitabine combined with cisplatin in the treatment of advanced bladder cancer is superior to gemcitabine plus cisplatin, which can improve the patients' survival time without significantly increasing the adverse reactions.
黄映勤, 刘玲, 刘爽, 徐苓傈, 汪宇. 吡柔比星、吉西他滨和顺铂联合治疗晚期膀胱癌的临床疗效及安全性[J]. 医学临床研究, 2019, 36(1): 95-97.
HUANG Yin-qing, LIU Ling, LIU Shuang, et al. Study on the Clinical Efficacy and Safety of Pirarubicin, Gemcitabine and Cisplatin in the Treatment of Advanced Bladder Cancer. JOURNAL OF CLINICAL RESEARCH, 2019, 36(1): 95-97.
2019, Vol. 36 
